Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Crizanlizumab (Adakveo®)	TA743 - Crizanlizumab for preventing sickle cell crises in sickle cell disease
Crizotinib	TA296 - Critzotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene TA529 - Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Cytarabine–daunorubicin liposomal (Vyxeos®)	TA552 - Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Dabigatran capsules	TA249 - Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation TA327 - Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	Following diagnosis of AF – use in line NICE and toolkit, initiation/recommendation by haematologist, transfer to GP with RICaD. For the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/recommendation by haematologist, transfer to GP with RICaD Adults only
Dabrafenib	TA321 - Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma TA544 - Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib with trametinib	TA898 - Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer
Daclizumab concentrate for infusion	TA441 - Daclizumab for treating relapsing–remitting multiple sclerosis	For Hospital Use Only. Please see drug safety alert. Safety alert
Dacomitinib	TA595 - Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
Daktacort cream	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Mild potency
Dapagliflozin	TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes TA418 - Dapagliflozin in triple therapy for treating type 2 diabetes TA775 - Dapagliflozin for treating chronic kidney disease	For treating Type 2 diabetes in line with NICE

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.